Hemogenyx Pharmaceuticals (LSE:HEMO) Forward Dividend Yield % : 0.00% (As of May. 22, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals Forward Dividend Yield %?

As of today (2024-05-22), the Forward Annual Dividend Yield of Hemogenyx Pharmaceuticals is 0.00%.

As of today (2024-05-22), the Trailing Annual Dividend Yield of Hemogenyx Pharmaceuticals is 0.00%.

LSE:HEMO's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.55
* Ranked among companies with meaningful Forward Dividend Yield % only.

Hemogenyx Pharmaceuticals's Dividends per Share for the six months ended in Dec. 2023 was £0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Hemogenyx Pharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's Forward Dividend Yield % falls into.

Hemogenyx Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Hemogenyx Pharmaceuticals (LSE:HEMO) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Hemogenyx Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals (LSE:HEMO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

5HU:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (LSE:HEMO) Headlines

No Headlines